Trial Results, page-48

This from novemebr 2017 announcement sounds positive. Could IMM124E be Immuron's next product ?

In July 2017, the Company announced its interim analysis results conducted by analysing a total of 122 patients, 80 of which completed  their 24‐week  treatment of IMM‐124E. In  this  report, IMM 124E demonstrated good safety features compared to the placebo. Additionally, the Data and Safety Monitoring Board (DSMB) reported that IMM‐124 demonstrated a statistically‐significant reduction in ALT – an enzyme most commonly found in the liver over time when the two treatment doses were compared to the placebo arm. The same effect was noted for AST – another enzyme found in the liver and a correlation between these two enzymes was also reported. These preliminary results suggest a reduction in liver injury (necro‐inflammation) over the duration of treatment compared to the placebo.
"We are now working diligently to analyse and collate all remaining data from our contracted laboratories and CROs,” said Immuron Head of Medical, Dr Dan Peres.  
“Following thorough analysis, we expect to report our top line results in Q1 CY2018. Based on the safety profile and the efficacy signal we reported earlier this year, we believe that the results generated by this analysis position IMM124E as a unique product for treating NASH patients on its own, or in combination with other promising treatments.”